A Phase I, Multi-center, Open-label Study to Investigate the Pharmacokinetic Interactions of RO5185416 with a "Cocktail" of Five Probe Drugs for CYP450 Dependent Metabolism in Patients with Previously Treated and Untreated Metastatic Melanoma.

Trial Profile

A Phase I, Multi-center, Open-label Study to Investigate the Pharmacokinetic Interactions of RO5185416 with a "Cocktail" of Five Probe Drugs for CYP450 Dependent Metabolism in Patients with Previously Treated and Untreated Metastatic Melanoma.

Completed
Phase of Trial: Phase I

Latest Information Update: 21 Aug 2017

At a glance

  • Drugs Vemurafenib (Primary) ; Caffeine; Dextromethorphan; Midazolam; Omeprazole; Vitamin K; Warfarin
  • Indications Malignant melanoma
  • Focus Pharmacokinetics
  • Sponsors Roche
  • Most Recent Events

    • 03 Mar 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 23 May 2013 Planned end date changed from 1 Oct 2013 to 1 Aug 2013 as reported by ClinicalTrials.gov.
    • 05 Jul 2012 Actual patient number changed from 16 to 22 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top